Sodium-GLucose coTransporter-2 Inhibitors
0
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Carmine TherapeuticsSingapore - Singapore
1 programSodium-GLucose coTransporter-2 inhibitorsN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
Carmine TherapeuticsSodium-GLucose coTransporter-2 inhibitors
Clinical Trials (1)
Total enrollment: 503 patients across 1 trials
Deformation Imaging by Strain in Chronic Heart Failure Over Gliflozins: an Echocardiographic Register on Sodium-GLucose coTransporter-2 Inhibitors
Start: Apr 2022Est. completion: Jun 2024503 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space